Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
Year: 2025
Type: article
Source: The Lancet Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of California, San Francisco, University of California San Francisco Medical Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Colorado Hospital, University of Colorado Anschutz, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4411848262